Changes in Inflammatory and Contractile Protein Expression in Patients With Painful Bladder Syndrome/IC.
CompletedNCT00775281
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Interstitial cystitis (IC)/chronic pelvic pain syndrome (CPPS) is a clinical syndrome of pelvic pain and/or urinary urgency/frequency in absence of a specific cause such as bacterial infection or damage to the bladder. The pathogenetic mechanisms of IC/CPPS are as yet undefined and it is largely this lack of knowledge, which precludes a systematic therapeutic approach. Experimental evidence, including results from the animal models of cystitis and the knock-out mice, indicate a participation of tachykinin receptors, especially the NK1R, in neurogenic inflammation, which is considered an important element of the IC complex. However, there is very scant information about the molecular mechanisms of IC in humans, or of the types of receptors, which participate in neurogenic inflammation. Based on our molecular biological know-how and the clinical expertise, we propose to investigate the role of the tachykinin and bradykinin receptors and their signalling partners in CPPS and bladder dysfunction in humans.
Study details
- Official title
- Mediators of Neurogenic Inflammation in the Urinary Tract as Key Factors in the Painful Bladder Syndrome / Interstitial Cystitis and Bladder Dysfunction
- Conditions
- Overactive Bladder
- Painful Bladder Syndrome
- Chronic Pelvic Pain Syndrome
- Cystitis, Interstitial
- Sponsor
- Insel Gruppe AG, University Hospital Bern
- Start date
- 2006-10
- Primary completion
- 2010-04
- Sex
- All
- Age range
- from 18 Years
- Healthy volunteers
- true
- Results posted
- No results posted in this snapshot
- Countries
- Switzerland
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Clinical asymptomatic bladder function * Clinical urgency frequency syndrome/ overactive bladder * Clinical painful bladder syndrome/interstitial cystitis Exclusion Criteria: * Not able to understand patient information * Other cause of symptoms * Confusable diseases
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00775281